You are here

SBIR Phase I: MIcrobial Modulation of Gastrointestinal Digestive Efficiency and Inflammation

Award Information
Agency: National Science Foundation
Branch: N/A
Contract: 1113684
Agency Tracking Number: 1113684
Amount: $150,000.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: BC
Solicitation Number: N/A
Timeline
Solicitation Year: 2010
Award Year: 2011
Award Start Date (Proposal Award Date): 2011-07-01
Award End Date (Contract End Date): 2012-06-30
Small Business Information
3807 Petre Rd
Springfield, OH 45502-8750
United States
DUNS: 965447365
HUBZone Owned: No
Woman Owned: Yes
Socially and Economically Disadvantaged: No
Principal Investigator
 Brenda Moore
 (937) 241-9443
 bemoore123@gmail.com
Business Contact
 Brenda Moore
Phone: (937) 241-9443
Email: bemoore123@gmail.com
Research Institution
 Stub
Abstract

This Small Business Innovation Research (SBIR) Phase I project is designed to provide a new probiotic product for public consumption that will address the rising US and global obesity issue and related concurrent increase in health problems such as diabetes and heart disease. According to the Centers for Disease and Prevention, 60-65% of the adult population in the US is overweight or obese. While implementation of lifestyle change (dietary modification and increased physical activity) improves this condition, relapse with additional weight gain is well documented. Current treatments are limited and include surgery and pharmacological agents with well documented health risks. This product is designed to work within the gastrointestinal tract, decreasing the amount of energy available to the host, and providing a means to the consumer to halt weight gain and decrease the risk of relapse, with possible positive modulation of underlying risk factors which contribute to declining health and contribute to increased health care costs. The broader/commercial impacts of this research will be to reduce the high incidence of obesity. The rising cost of health care in the US has been well documented. Much of this cost is associated with increasing obesity, an underlying factor in the development of diseases such as diabetes and heart disease, commonly associated with an increase in abdominal circumference/inflammatory processes. According to the World Health Organization, three-fourths of the world population depends upon some form of non-pharmaceutical product for health care, providing a world-wide marketing opportunity for future commercialization.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government